Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 13/20 | 1.00 |
| ▸ | DRD3 | P35462 | 13/20 | 1.00 |
| ▸ | DRD2 | P14416 | 11/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | UQCRB | P14927 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13219278 | 1.00 | KCNH2 (1.00) | KCNH2DRD3DRD2SLC6A2SLC6A4 | |
| SCHEMBL13201893 | 0.85 | KCNH2 (1.00) | KCNH2DRD3DRD2SLC6A2SLC6A4 | |
| SCHEMBL2976295 | 0.85 | KCNH2 (1.00) | KCNH2DRD3DRD2SLC6A2SLC6A4 | |
| SCHEMBL13219171 | 0.85 | KCNH2 (1.00) | KCNH2DRD3DRD2SLC6A2SLC6A4 | |
| SCHEMBL13201895 | 0.83 | KCNH2 (0.73) | KCNH2DRD3DRD2SLC6A2SLC6A4 | |
| SCHEMBL13219296 | 0.83 | KCNH2 (0.73) | KCNH2DRD3DRD2SLC6A2SLC6A4 | |
| SCHEMBL13219279 | 0.81 | DRD3 (1.00) | KCNH2DRD3DRD2CYP1A2CYP3A4 | |
| SCHEMBL13201897 | 0.81 | DRD3 (1.00) | KCNH2DRD3DRD2CYP1A2CYP3A4 | |
| SCHEMBL2965790 | 0.81 | KCNH2 (1.00) | KCNH2DRD3DRD2SLC6A2SLC6A4 | |
| SCHEMBL13201890 | 0.81 | KCNH2 (1.00) | KCNH2DRD3DRD2SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776904-B2 | Azabicyclo [3.1.0] hexylphenyl derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2010-08-17 | — | — | US | disclosed |
| US-20090030062-A1 | AZABICYCLO [3.1.0] HEXYLPHENYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030062-A1 | AZABICYCLO [3.1.0] HEXYLPHENYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | DRD3, DRD2, HTR3C | KCNH2 1057/4885DRD3 1/4885DRD2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.